Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Hospitalization in Amyotrophic Lateral Sclerosis, Causes, Costs, and Outcomes
Neurol 56:753-757, Lechtzin,N.,et al, 2001
Home Ventilation for ALS Patients:Outcomes, Costs, and Patient, Family and Physician Attitudes
Neurol 43:438-443, Moss,A.H.,et al, 1993
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Imaging the Brain, Part 1 & 2
NEJM 338:812-820, 889-8961998., Gilman,S., 1998
Tolterodine for Overactive Bladder
The Medical Letter 40:101-102, , 1998
Glatiramer Acetate for Relapsing Multiple Sclerosis
The Medical Letter 39:61-62, , 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Problems with Myofascial Pain Syndrome and Fibromyalgia Syndrome
Neurol 46:593-597, Bohr,T., 1996
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996
The Hidden Costs of Medicolegal Abuses in Neurology
Arch Neurol 51:650-652, Scheinberg,P., 1994
Update on Surgical Treatment of the Epilepsies, Second Intern Palm Desert Conf on Surgical Trtm of Epilepsies (1992)
Neurol 43:1612-1617, Engel,J.Jr., 1993